Revance Therapeutics Inc (RVNC)

[Emannow]

Scott Reents (AbbVie)
"Given slower-than-expected near-term market growth, particularly in the U.S. and China, as a result, our total sales guidance for Botox and Juvederm will each be lower by roughly $100 million".

Botox lower by $100 million AND Juvederm lower by $100 million....

Interesting as US sales for Evolus, Galderma and Revance are all growing at double digits... but the same US market is not growing in Allergan's Analytics....Humm...maybe Allergan needs to hire a new Analytics Group.

And Botox unit sales are still below their 2 year level.